Corrigendum

Area of Science:

• Immunology
• Pharmacology
• Molecular Biology

Background:

• CD4(+) T lymphocytes play a crucial role in autoimmune diseases.
• Phosphatidyl inositol 3-kinase (PI3K) signaling is vital for T cell activation.
• Developing targeted inhibitors for PI3K is a potential therapeutic strategy.

Purpose of the Study:

• To investigate the effects of the PI3K inhibitor PIK-75 on CD4(+) T lymphocyte activation.
• To evaluate the efficacy of PIK-75 in a mouse model of experimental autoimmune encephalomyelitis (EAE).

Main Methods:

• In vitro studies assessed CD4(+) T cell activation markers.
• In vivo studies utilized an experimental autoimmune encephalomyelitis model in mice.
• PIK-75 was administered to T cells and EAE model.

Main Results:

• PIK-75 significantly suppressed CD4(+) T lymphocyte activation in vitro.
• PIK-75 treatment reduced the severity of experimental autoimmune encephalomyelitis in vivo.
• PIK-75 demonstrated immunomodulatory effects.

Conclusions:

• PIK-75 effectively inhibits CD4(+) T cell activation and ameliorates experimental autoimmune encephalomyelitis.
• PIK-75 represents a potential therapeutic agent for T cell-mediated autoimmune disorders.
• Targeting PI3K signaling is a promising approach for treating autoimmune diseases.